FDA Delays Moderna Covid-19 Vaccine for Adolescents to Review Rare Myocarditis Side Effect

FDA Delays Moderna Covid-19 Vaccine for Adolescents to Review Rare Myocarditis Side Effect

Moderna asked the Food and Drug Administration in June to expand use of the company’s Covid-19 vaccine to 12-to-17-year-olds, but the agency has held off while it looks into the risk of myocarditis, a rare heart condition.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting